Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Innovent Biologics (1801) Stock Price & Analysis

29 Followers

1801 Stock Chart & Stats

HK$86.80-HK$1.50(-1.70%)
At close: 4:00 PM GMT+8
HK$80HK$90HK$100HK$110Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 85.20 - HKD 88.30
52-Week Range
HKD 69.55 - HKD 112.70
Previous Close
HKD 88.30
Volume
N/A
Average Volume (3M)
9.86M
Market Cap
HKD 154.34B
Enterprise Value
HKD 122.92B
Total Cash (Recent Filing)
HKD 20.00B
Total Debt (Recent Filing)
HKD 2.32B
Price to Earnings (P/E)
106.4
Beta
0.73
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
1.31
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Profit Inflection

The 2025 return to profitability alongside substantial revenue growth indicates improving commercial scale and operating execution. If this performance persists, a larger revenue base can support continued investment in the biologics portfolio and strengthen the company’s earnings foundation.

Strong Cash Generation

Strong operating and free cash flow materially improve Innovent’s ability to fund research, development, manufacturing, and commercialization internally. This reduces reliance on external financing and gives the company greater flexibility to advance its pipeline and support ongoing operations.

Conservative Balance Sheet

Low and declining leverage, combined with a larger equity base, provides financial resilience as Innovent funds development and commercial activities. A stronger capital structure can help the company absorb operating volatility and preserve strategic flexibility across its drug portfolio.

Bears Say

Unproven Profitability Durability

The recent profit improvement is encouraging, but the preceding multi-year period of operating losses shows that sustainable earnings have not yet been firmly established. Continued execution will be required to demonstrate that the 2025 inflection reflects durable economics rather than a temporary improvement.

Modest Net Profitability

The gap between very strong gross profitability and relatively modest net profitability suggests substantial costs remain below gross profit. This limits the amount of revenue that converts into earnings and leaves future results sensitive to continued spending and operating execution.

Uneven Historical Cash Flow

The sharp 2025 cash-flow recovery has not yet been supported by a consistent multi-year record. Earlier cash deficits indicate that Innovent’s cash generation can be volatile, creating uncertainty about how reliably future internal funding can support pipeline investment and expansion.

Innovent Biologics News

1801 FAQ

What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$69.55 and its highest was HK$112.70 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is HK$154.34B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 139 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 25, 2026. The company reported HK$0.824 earnings per share for the quarter, beating the consensus estimate of HK$0.553 by HK$0.271.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 1.31.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,747,871,800 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of HK$0.824 in its last earnings report, beating expectations of HK$0.553. Following the earnings report the stock price went up 0.603%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology